Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
Open accessThe DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index.
Abstract
Cetuximab and panitumumab, as the highly effective antibodies targeting epidermal growth factor receptor (EGFR), have clinical activity in the patients with metastatic colorectal cancer (mCRC). These agents have good curative efficacy, but drug resistance also exists at the same time. The effects of KRAS, NRAS, and BRAF mutations and HER2 amplification on the treatment of refractory mCRC have been elucidated and the corresponding countermeasures have been put forward. However, the changes in EGFR and its ligands, the mutations or amplifications of PIK3CA, PTEN, TP53, MET, HER3, IRS2, FGFR1, and MAP2K1, the overexpression of insulin growth factor-1, the low expression of Bcl-2-interacting mediator of cell death, mismatch repair-deficient, and epigenetic instability may also lead to drug resistance in mCRC. Although the emergence of drug resistance has genetic or epigenetic heterogeneity, most of these molecular changes relating to it are focused on the key signaling pathways, such as the RAS/RAF/mitogen-activated protein kinase or phosphatidylinositol 3-kinase/Akt/mammalian target of the rapamycin pathway. Accordingly, numerous efforts to target these signaling pathways and develop the novel therapeutic regimens have been carried out. Herein, we have reviewed the underlying mechanisms of the resistance to anti-EGFR therapy and the possible implications in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Elevated plasma levels of EGFR ligands such as epiregulin (EREG) and amphiregulin (AREG) may be indicative of resistance to anti-EGFR therapy [29].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [29]
In the citing paper
“Whereas PI3K inhibitors and mTOR inhibitors have been developed and approved for clinical trials in PIK3CA-mutated solid tumors [164].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [164]
In the citing paper
“There is increasing evidence that aberrant activation of this pathway is associated with anti-EGFR treatment resistance [164].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [164]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“8 million new CRC cases and 881,000 deaths were estimated to have occurred in 2018 and the incidence and mortality rank third and second, respectively [1].”
BackgroundBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“Among them, BRAF accounts for >90% of BRAF mutations, which refers to the T-to-A changing at nucleotide 1799 and a substitution of valine to glutamic acid [64].”
BackgroundComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Global patterns and trends in colorectal cancer incidence and mortality
Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2017) · Gut · doi:10.1136/gutjnl-2015-310912 · Cited by 5,228 · cited 1×
“Fortunately, although the incidence and mortality of CRC in some underdeveloped areas are still increasing, they are declining in the whole world, especially in the developed countries [3].”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions*
JONES, J. I., & CLEMMONS, D. R. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-3 · Cited by 4,710
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · cited 1×
“transcription 3 (STAT3) [124]; besides, HGFR can also be coupled with HER3 to form a heterodimer under certain conditions [125].”
Background
Cited by
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
The Role of EREG/EGFR Pathway in Tumor Progression
Cheng, W.-L., Feng, P.-H., Lee, K.-Y., Chen, K.-Y., Sun, W.-L., Van Hiep, N., Luo, C.-S., & Wu, S.-M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312828 · Cited by 239
“Although patients with metastatic colorectal cancer (mCRC) exhibited a high efficacy to anti-EGFR antibodies such as cetuximab or panitumumab, drug resistance was also observed in cancer cells [90,91].”
BackgroundThe path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 180
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges
Janani, B., Vijayakumar, M., Priya, K., Kim, J. H., Prabakaran, D. S., Shahid, M., Al-Ghamdi, S. H., Alsaidan, M. S., Bahakim, N. O., Abdelzaher, M. H., et al. (2022) · Vaccines · doi:10.3390/vaccines10040499 · Cited by 126
“EGF, transforming growth factor (TGF-), β-cellulin, epiregulin (EREG), epigen (EPGN), amphiregulin (AREG), and heparin-binding EGF are the most common EGFR ligands[24].”
BackgroundMirzaei, S., Gholami, M. H., Hashemi, F., Zabolian, A., Hushmandi, K., Rahmanian, V., Entezari, M., Girish, Y. R., Kumar, K. S. S., Aref, A. R., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119430 · Cited by 98
A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer
Subramaniyan, V., Fuloria, S., Gupta, G., Kumar, D. H., Sekar, M., Sathasivam, K. V., Sudhakar, K., Alharbi, K. S., Almalki, W. H., Afzal, O., et al. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109735 · Cited by 94
Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer
Tufail, M., Wan, W., Jiang, C., & Li, N. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111055 · Cited by 81
Ginghină, O., Hudiță, A., Zamfir, M., Spânu, A., Mardare, M., Bondoc, I., Buburuzan, L., Georgescu, S. E., Costache, M., Negrei, C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.856575 · Cited by 80
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Elevated plasma levels of EGFR ligands such as epiregulin (EREG) and amphiregulin (AREG) may be indicative of resistance to anti-EGFR Cetuximab and panitumumab treatment results in similar survival benefit. anti-EGFR therapy [29].”
BackgroundNanotechnology for colorectal cancer detection and treatment
Gogoi, P., Kaur, G., & Singh, N. K. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i46.6497 · Cited by 82
Bazzichetto, C., Milella, M., Zampiva, I., Simionato, F., Amoreo, C. A., Buglioni, S., Pacelli, C., Pera, L. L., Colombo, T., Bria, E., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102631 · Cited by 69
“Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer death worldwide [1].”
BackgroundProteomics of post-translational modifications in colorectal cancer: Discovery of new biomarkers
Zhu, G., Jin, L., Sun, W., Wang, S., & Liu, N. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188735 · Cited by 68
Racial and Ethnic Disparities in Early-Onset Colorectal Cancer Survival
Zaki, T. A., Liang, P. S., May, F. P., & Murphy, C. C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.05.035 · Cited by 70
Lawler, T., Parlato, L., & Andersen, S. W. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1349572 · Cited by 69
El Hallal, R., Lyu, N., & Wang, Y. (2021) · Molecules · doi:10.3390/molecules26030567 · Cited by 51
“Although the use of cetuximab has greatly improved the clinical outcomes of metastatic CRC, the discovery of resistance to anti-EGFR monoclonal antibodies stimulated interest in the study of drug resistance, including abnormal molecules in the EGFR pathway, abnormal activations between the paralleled pathways, and oth…”
BackgroundSelf-citationSERS characterization of colorectal cancer cell surface markers upon anti‐EGFR treatment
Lyu, N., Pedersen, B., Shklovskaya, E., Rizos, H., Molloy, M. P., & Wang, Y. (2022) · Exploration · doi:10.1002/exp.20210176 · Cited by 51
Self-citationNafie, M. S., Kishk, S. M., Mahgoub, S., & Amer, A. M. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13997 · Cited by 49
“Several studies have demonstrated that inhibiting EGFR and downstream signaling may lead to cell growth inhibition of carcinoma, resulting in significant benefits for cancer therapy (Li et al., 2020).”
BackgroundDailah, H. G., Hommdi, A. A., Koriri, M. D., Algathlan, E. M., & Mohan, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24559 · Cited by 48
Yanghe decoction inhibits inflammation-induced lung metastasis of colorectal cancer
Zhang, L., Liu, S., Ding, K., Zeng, B., Li, B., Zhou, J., Li, J., Wang, J., Su, X., & Sun, R. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119257 · Cited by 44
Manzi, J. L. L., Hoff, C. O., Ferreira, R., Pimentel, A., Datta, J., Livingstone, A. S., Vianna, R., & Abreu, P. (2023) · Cancers · doi:10.3390/cancers15113023 · Cited by 47
“The incidence of RAS mutations in CRC is about 53% [78], mainly in codons 12 or 13 of exon 2 (81–96% of all KRAS mutations), and 4–19% at exon 3 or exon 4 [66,79,80].”
BackgroundKeshavarz, F., Dorfaki, M., Bardania, H., Khosravani, F., Nazari, P., & Ghalamfarsa, G. (2023) · PubMed Central · doi:10.30476/ijms.2022.95272.2658 · Cited by 38
Current concepts of anti-EGFR targeting in metastatic colorectal cancer
Doleschal, B., Petzer, A., & Rumpold, H. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1048166 · Cited by 40
Hajjafari, A., Sadr, S., Rahdar, A., Bayat, M., Lotfalizadeh, N., Dianaty, S., Rezaei, A., Moghaddam, S. P., Hajjafari, K., Simab, P. A., et al. (2024) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2024.112409 · Cited by 39
Tardito, S., Matis, S., Zocchi, M. R., Benelli, R., & Poggi, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137131 · Cited by 34
“%) can occur [14].”
BackgroundHjazi, A. M., Nasir, F., Noor, R., Alsalamy, A., Zabibah, R. S., Romero‐Parra, R. M., Ullah, M. I., Mustafa, Y. F., Qasim, M. T., & Akram, S. V. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154616 · Cited by 53
Benavides, M., Alcaide, J., Torres, E., Gil-Calle, S., Sevilla, I., Wolman, R., Durán, G., Álvarez, M., Reyna-Fortes, C., Díaz, I. A., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100481 · Cited by 30
“The National Comprehensive Cancer Network (NCCN) guidelines, the European Society for Medical Oncology (ESMO) recommendations for use of next-generation sequencing (NGS), and the Pan-Asian adapted ESMO consensus guidelines recommend testing for KRAS, NRAS, and BRAF V600E mutations as part of workup for suspected, or c…”
BackgroundChee, C. W., Zamakshshari, N. H., Lee, V. S., Abdullah, I., Othman, R., Lee, Y. K., Hashim, N. M., & Rashid, N. N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270970 · Cited by 35
“Moreover, patients harboring KRAS mutation generally acquire resistance to anti-epidermal growth factor receptor (EGFR) therapy, conferring poor survival [11].”
BackgroundHER2-targeted therapy in colorectal cancer: a comprehensive review
Benli, Y., Arıkan, H., & Akbulut, Ö. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03887-0 · Cited by 30
“Likewise, PDXs with HER2 mutations retained their tumor regression after dual treatment of anti-HER2 therapies (trastuzumab plus neratinib or trastuzumab plus lapatinib) compared to single agents [25, 36].”
Hamdan, A., & Ewing, A. (2022) · The Journal of Pathology · doi:10.1002/path.5901 · Cited by 34
Son, S., Kim, H., Lim, H., Lee, J.-H., Lee, K., & Shin, I. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05608-3 · Cited by 30
“Currently, various tyrosine kinase inhibitors or monoclonal antibodies that inhibit EGFR have been developed and used as therapeutic agents for cancers like nonsmall cell lung cancer and metastatic colorectal cancer [23, 24].”
BackgroundZhang, Q., Zheng, Y., Liu, J., Tang, X., Wang, Y., Li, X., Li, H., Zhou, X., Tang, S., Tang, Y., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-022-05536-8 · Cited by 27
“Besides, other unknown mutations related to dMMR/pMMR or epigenetic instability may also exert influence in the cetuximab resistance [33, 39].”
BackgroundSelf-citationYuan, H.-H., Zhang, X., Wei, X.-L., Zhang, W., Du, X., Huang, P., Chen, H., Bai, L., Zhang, H., & Han, Y. (2021) · Journal of Cancer · doi:10.7150/jca.65687 · Cited by 26
“As cetuximab binds competitively and has high affinity for EGFR, we focused on the major EGFR activation-induced downstream signalling pathways, which are also involved in resistance to EGFR inhibitors [51].”
BackgroundMolecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
Canale, M., Monti, M., Rapposelli, I. G., Ulivi, P., Sullo, F. G., Bartolini, G., Tiberi, E., & Frassineti, G. L. (2021) · Cancers · doi:10.3390/cancers13225671 · Cited by 24
“EGFR was the first of the family discovered as proto-oncogene, and its expression alterations and mutations has been shown in many cancer cells; moreover, it is a recognized molecular target for precision medicine in molecularly selected lung and colon cancers [24,25].”
BackgroundClonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer
Anupriya, S., Chakraborty, A., & Patnaik, S. (2022) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2022.108445 · Cited by 26
HER2 targeted therapy in colorectal Cancer: Current landscape and future directions
Chen, N., He, L. T., Zou, Q., & Deng, H. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116101 · Cited by 23
HER3 Alterations in Cancer and Potential Clinical Implications
Kilroy, M. K., Park, S., Feroz, W., Patel, H., Mishra, R., Alanazi, S., & Garrett, J. T. (2022) · Cancers · doi:10.3390/cancers14246174 · Cited by 21
“Although HER2 is HER3′s preferred dimerization partner, the commonality of HER3 amplifications and mutations may leave it with a higher possibility of dimerizing with EGFR [97].”
BackgroundColon Cancer Pharmacogenetics: A Narrative Review
Alfaro, Á. E. A., Murillo-Castillo, B., García, E. C., Tascón, J., & Morales, A. I. (2022) · Pharmacy · doi:10.3390/pharmacy10040095 · Cited by 19
“Today, it is mainly used in combination with other chemotherapeutic agents, as shown in Table 2 [42,43].”
BackgroundLawler, T., Parlato, L., & Andersen, S. W. (2023) · Cancer Causes & Control · doi:10.1007/s10552-023-01783-y · Cited by 21
“EGFR inhibition via monoclonal antibodies that competitively bind and inhibit the extracellular ligand-binding domain (e.g., cetuximab and panitumumab) is an established treatment for metastatic CRC and significantly increases progression-free survival [19].”
Wu, J., Li, X., Liu, H., Liu, Y.-J., & Liu, X. (2023) · Biomedical Reports · doi:10.3892/br.2023.1686 · Cited by 20
“RAS (KRAS/NRAS) is a proto‑oncogene that encodes a protein with GTPase activity that plays a role in EGFR signal transduction and self‑inactivation (11).”
BackgroundGmeiner, W. H. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s242224 · Cited by 18
“be monitored to provide an indication of resistance to antiEGFR therapy.(24) EGFR gene copy number and acquired”
BackgroundTargeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
Veiga, R. N., de Azevedo, A. L. K., de Oliveira, J. C., & Gradia, D. F. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02431-x · Cited by 21
Cheng, Y., Chen, M., Yadav, V. K., Pikatan, N. W., Fong, I.-H., Kuo, K.-T., Yeh, C., & Tsai, J. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102274 · Cited by 18
Liu, T., Jiang, S., Teng, X., Zhong, L., Liu, M., Jin, Y., & Dong, M. (2023) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2022.2112222 · Cited by 17
“As highly effective antibodies targeting EGFR, cetuximab and panitumumab have better clinical activity in the patients with mCRC [7].”
BackgroundThe emerging era of personalized medicine in advanced colorectal cancer
Wu, C. W., Reid, M., Leedham, S. J., & Lui, R. N.-S. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15937 · Cited by 21
Colorectal cancer: Review of signaling pathways and associated therapeutic strategies
Leiphrakpam, P. D., Rajappa, S. J., Krishnan, M., Batra, R., Murthy, S. S., & Are, C. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27295 · Cited by 18
Abbass, E. M., Al-Karmalawy, A. A., Sharaky, M. M., Khattab, M., Alzahrani, A. Y. A., & Hassaballah, A. I. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106936 · Cited by 16
The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients
Fu, X., Lin, H., Fan, X., Zhu, Y., Wang, C., Chen, Z., Tan, X., Huang, J., Cai, Y., & Huang, Y. Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.595675 · Cited by 17
Cann, C., LaPelusa, M. B., Cimino, S. K., & Eng, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176950 · Cited by 17
Precision medicine in colorectal cancer: genomics profiling and targeted treatment
Muhar, A. M., Velaro, A. J., Prananda, A. T., Nugraha, S. E., Halim, P., & Syahputra, R. A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1532971 · Cited by 15
Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation
Sun, F., Yao, F., Zeng, C., Zhao, Y., Liang, B., Li, S., Wang, Y., Wu, Q., Shi, Y., Yao, Z., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010126 · Cited by 14
Self-citationInnovative laboratory techniques shaping cancer diagnosis and treatment in developing countries
Lawal, A. O., Ogunniyi, T. J., Oludele, O. I., Olorunfemi, O. A., Okesanya, O. J., Ogaya, J. B., Manirambona, E., Ahmed, M. M., & Lucero‐Prisno, D. E. (2025) · Discover Oncology · doi:10.1007/s12672-025-01877-w · Cited by 14
Chu, Y. C., Tsai, T.-Y., Yadav, V. K., Deng, L., Huang, C.-C., Tzeng, Y., Yeh, C., & Chen, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147508 · Cited by 13
“Ras-signaling is involved in anti-EGFR therapy because Ras-protein overexpression causes the inhibitory signal from EGFR [37].”
BackgroundKubaichuk, K. I., Seitz, T., Bergmann, U., Glumoff, V., Mennerich, D., & Kietzmann, T. (2024) · Oncogenesis · doi:10.1038/s41389-024-00538-x · Cited by 12
“However, it has become apparent that a high number of CRC patients develop resistance to those EGFR targeting therapies [5], showing that the search for molecular targets that are involved in drug resistance development is of great importance.”
BackgroundJian-lan, H., Liang, L., Xie, P., Sun, W., Wang, L., & Cai, Z. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12183 · Cited by 11
“Although targeted therapies and immunotherapies have improved the treatment outcomes of advanced CRC, the therapeutic efficacy is still limited, espe‑ cially because the development of drug resistance affects the further improvement of therapeutic efficacy (3,4).”
BackgroundDehghan, R., Bahreini, F., Najafi, R., Saidijam, M., & Amini, R. (2021) · BioMed Research International · doi:10.1155/2021/6635874 · Cited by 11
“The mutations of EGFR, the low expression of EGFR, and the changes in its ligands have been shown to be related to drug resistance [43].”
BackgroundMeng, X. (2025) · Journal of Cancer Biomoleculars and Therapeutics · doi:10.62382/jcbt.v2i1.32 · Cited by 11
Anticancer potential of dietary fiber for colorectal carcinoma: a narrative review
Hussain, M. B., Albukhari, A. F., Rafeeq, M. M., Imran, M., Albagholi, A. H., & Assedoodi, M. A. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2583756 · Cited by 10
“The development of drug resistance, persistent cancer stem cells and high intratumoral heterogeneity can be the reason which leads to a suboptimal response [14,15].”
de Moraes, F. C. A., Rodrigues, A. L. S. D. O., Priantti, J. N., Limachi-Choque, J., & Burbano, R. M. R. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01128-1 · Cited by 11
Akbarzadeh-Khiavi, M., Farzi-Khajeh, H., Somi, M. H., Safary, A., Barar, J., Ansari, R. A., & Omidi, Y. (2022) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2022.129890 · Cited by 10
Precision Medicine in Colorectal Cancer: Targeted Therapies and Biomarker Insights
Srivastava, S., Anand, A. K., Kandhula, A. G., Jaiswal, P., Kumar, S., Gulati, M., Sachdeva, M., & Behl, T. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096338273241224061021 · Cited by 14
Spendlove, M., Gibson, T. M., McCain, S., Stone, B. C., Gill, T., & Pickett, B. E. (2023) · PeerJ · doi:10.7717/peerj.16088 · Cited by 9
Advances and challenges in drug repurposing in precision therapeutics of colorectal cancer
Yu, X., Wu, H.-T., Wu, B., Zhi, S.-F., Lan, Y.-Z., Chen, W.-J., & Liu, J. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i7.107681 · Cited by 9
“In CRC, mutations in KRAS , NRAS , and BRAF lead to its constitutive activation, driving uncontrolled tumor growth and metastasis[102].”
Next Generation Calcium Nanomaterials: Disrupting Tumor Ca2⁺ Homeostasis for Enhanced Cancer Therapy
Gangadhar, L., Sana, S. S., Venkatesan, R., Bhandare, R. R., Kim, S.-C., & Yasin, H. K. A. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s557935 · Cited by 8
Hassan, A. F., Hussein, O., Al-Barazenji, T., Allouch, A., Kamareddine, L., Malki, A. M., Moustafa, A. A., & Khalil, A. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27002 · Cited by 7
“Various studies have; however, reported that RAS mutant subtypes are resistant to anti-EGFR treatments beside the absence of Wnt inhibitor in clinical practice [21 – 24], necessitating the development of novel and effective therapeutic compounds against KRAS mutant CRCs as an alternative.”
BackgroundUp-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer
Cimino, S. K., & Eng, C. (2020) · Journal of Experimental Pharmacology · doi:10.2147/jep.s259287 · Cited by 9
The Radiolabeled HER3 Targeting Molecules for Tumor Imaging.
Molavipordanjani, S., & Hosseinimehr, S. J. (2021) · PubMed Central · doi:10.22037/ijpr.2021.114677.14991 · Cited by 9
Chauhan, S., & Sharma, S. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010270975231208113157 · Cited by 6
Cuffaro, D., Gregorio, L. D., Mangini, C., Taglieri, M., Matis, S., Benelli, R., Ardy, M., Salvini, L., Rossello, A., Poggi, A. D., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-22669-w · Cited by 6
“This is the main reason as this antibody is used for the treatment of some metastatic CRC 35 .”
Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance
Tak, E., Kim, M., Cho, Y.-R., Choi, S., Kim, J., Han, B., Kim, H., Jang, C. S., Kim, J. H., Hong, Y. S., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8226 · Cited by 6
“However, therapeutic approaches that were proposed for overcoming resistance to anti‐EGFR therapy thus far have rarely been able to confer clinical benefits (5,6).”
BackgroundDing, C., Yao, R., Wang, Y., Liu, H., Li, C., & Xie, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1656372 · Cited by 7
“Phosphorylation is the most widely studied post-transcriptional modi fi cation, and the common protein phosphorylation involved in acquired anti-EGFR resistance in CRC is the activation of the RAF/RAS/MEK/ERK and PI3K/AKT/mTOR signaling pathways (Li et al., 2020).”
Self-citationSu, Y., Su, C., Lee, P., & Wu, C. (2025) · Annals of Coloproctology · doi:10.3393/ac.2025.00059.0008 · Cited by 6
Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries
Shouki, B., Abdelsalam, A., Abdullah, A. S., Alshammari, K. M., Ahmed, A. M., Dawoud, E., Heinemann, V., Mohamed, A., Chehal, A. A., Mohammed, A., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241299324 · Cited by 7
“47,48 Importantly, there is currently no evidence regarding the first-line use of HER-directed agents.”
The Significant Impacts of Interleukin-8 Genotypes on the Risk of Colorectal Cancer in Taiwan
Tsai, C.-W., CHANG, W.-S., YUEH, T.-C., WANG, Y.-C., Chin, Y.-T., Yang, M., Hung, Y., Mong, M., Yang, Y., Gu, J. H., et al. (2023) · Cancers · doi:10.3390/cancers15204921 · Cited by 5
Self-citationAnsari, D., Rystedt, J. L., Søreide, K., Lindberg, M., & Andersson, R. (2025) · Clinical & Experimental Metastasis · doi:10.1007/s10585-025-10357-y · Cited by 4
Zhou, Y., Zhao, X., Lu, N., Cao, P., Leng, W.-B., Zhu, Q., Gou, H., Zhang, J., Li, X., & Qiu, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111887 · Cited by 4
Diagnostic innovations and therapeutic potential of nanoparticulate delivery for colon cancer
Roy, A., Adnan, M., Ghosh, V., & Ajazuddin, M. (2024) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2024.101426 · Cited by 4
Colorectal cancer biomarkers and their impact on the clinical practice
Crespo, J., Victorino, A. P., Araujo, K., Araujo, L. H., & Vieira, F. M. D. A. C. (2021) · Brazilian Journal of Oncology · doi:10.5935/2526-8732.20210025 · Cited by 5
“[86] Therefore, screening for such alterations through more sensi - tive and less invasive approaches after EFGR-therapy resistance might be a trend.”
A novel management scheme for power grid demand response based on blockchain
Wang, G., Hairong, Z., Liu, Y., Yan, Q. Y., Dazhi, Z., Xiu-li, L., Wang, Y., & Guo, W. (2023) · Frontiers in Energy Research · doi:10.3389/fenrg.2023.1183117 · Cited by 3
Self-citationHuang, A. H., Lee, G. Y., Lu, C. A., Şahin, İ. H., King, G. T., Safyan, R. A., Cohen, S. A., Zhen, D. B., Shankaran, V., Harris, W. P., et al. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00646 · Cited by 4
A machine learning-based pharmacokinetics predictor (EGFR-PROPK) for EGFR-targeting PROTACs
Zhang, R., Li, F., Liu, Y., Geng, Y., Zhou, Y., Zeng, L., & Bai, F. (2026) · Communications Chemistry · doi:10.1038/s42004-026-01938-3 · Cited by 3
“The identi fi cation of EGFR as an oncogene has led to the development of targeted anticancer therapies, known as EGFR inhibitors, including drugs,suchasge fi tinib 31 ,erlotinib 32 ,afatinib 33 ,andicotinib 34 forlungcancer, aswellascetuximabforcoloncancer 35 .”
Targeting cell death: a promising approach for colorectal cancer therapy
Xiao, C., Oyang, L., Jiang, X., Li, S., & Peng, Q. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04261-y · Cited by 3
“Additionally, ERK signaling can upregulate MMPs, leading to the degradation of the extracellular matrix and promoting cancer cell migration and invasion [154, 155].”
Al‐Tamimi, A. O., Elemam, N. M., Hafezi, S., Saber-Ayad, M. M., & Talaat, I. M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1807304 · Cited by 3
“Conversely, studies have indicated that CRC patients with these mutations, particularly those with metastatic disease, have worse clinical outcomes and are less responsive to anti-EGFR monoclonal antibody therapy (Li et al., 2020).”
Ahmad, A., Tiwari, R. K., Siddiqui, S., Chadha, M., Shukla, R., & Srivastava, V. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2023.11.006 · Cited by 3
Zhou, Y., Wu, S., & Qu, F.-J. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i6.2362 · Cited by 3
Mekzali, N. W., Chee, C. W., Abdullah, I., Lee, Y. K., Rashid, N. N., Lee, V. S., Othman, R., Hashim, N. M., & Chee, C. F. (2023) · Medicinal Chemistry · doi:10.2174/1573406419666230410134213 · Cited by 2
Zhai, K., Liu, G., Cao, C., & Wang, X. (2025) · Oncology Letters · doi:10.3892/ol.2025.14908 · Cited by 3
“Previous studies have also explored new targets and combinations to enhance the specificity and effec‑ tiveness of these treatments (4,5).”
Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer
Chen, Z., Chen, J., Gao, Y., & Quan, M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1944108 · Cited by 2
“therapies and the majority of these patients eventually become refractory to the treatment [3].”
BackgroundMathavan, M., Mathavan, A., Mathavan, A., & Altshuler, E. (2022) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096221121406 · Cited by 2
Targeting long non-coding RNAs as new modulators in anti-EGFR resistance mechanisms
Akbarzadeh-Khiavi, M., Safary, A., & Omidi, Y. (2023) · Bioimpacts · doi:10.34172/bi.2023.27696 · Cited by 2
“10 However, in mCRC patients, the therapeutic response to anti-EGFR therapy can be limited due to the development of multiple resistance mechanisms.”
BackgroundHenrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“Despite strong preclinical evidence, clinical targeting of IGF-1R requires more clinical evidence to support its therapeutic application [39].”
Research Progress on the Role of EGFR in Tumorigenesis, Development and Treatment
吕, 烨. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14123150 · Cited by 1
Erciyestepe, M., Aydın, O., Sonuşen, Ş. D., Öztürk, A. E., Çelik, E., Atçı, M. M., & Ertürk, K. (2025) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001755 · Cited by 1
Kumar, T., Kesh, N., Pandey, A. K., Chakrawal, A., Singh, B., Pal, M., Rajput, M., Dixit, R., Pai, E., & Pandey, M. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04044-3 · Cited by 1
“5 Forest plots—adverse effects upregulation, thus sustaining proliferation independent of EGFR signalling [38–40].”
Functionalized nanocarriers via surface biomolecules ligation for colorectal cancer treatment
Srivastava, P., Sharma, A., Sharma, N., Ghosh, M., Pathak, S., Bera, R., Arora, A., & Karwasra, R. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107890 · Cited by 1
Liu, L., 陈颖君, Guo, M., Yun, F., Li, X., Chen, L., Li, Y. M., & Li, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1782130 · Cited by 1
“Although resistance arises through genetically and epigenetically heterogeneous mechanisms, the molecular alterations implicated predominantly converge on core signaling axes (Li et al., 2020).”
Korkmaz, M., Eryılmaz, M. K., Karaağaç, M., Araz, M., Çeneli, Ö., & Artaç, M. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001333 · Cited by 1
Aisyah, A., Tan, M. I., & Fibriani, A. (2024) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2024.00587 · Cited by 1
Resource-location patterns and state severance taxes: some empirical evidence
Richardson, J. A., & Scott, L. C. (1983) · UNM’s Digital Repository (University of New Mexico) · Cited by 1
Comparison of KRAS Mutation Status with Clinical Parameters in Colon Adenocarcinoma
BOYLU, B., & Türkmen, M. (2021) · Karadeniz Fen Bilimleri Dergisi · doi:10.31466/kfbd.981849
“When surgical intervention is not enough, anti - EGFR treatment where EGFR monoclonal antibodies such as cetuximab or panitumumab are used (Li et al., 2020).”
Metadata
- Authors
- Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N.
- Affiliations
- Department of Gastrointestinal Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P. R. China
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Venue
- Gastroenterology Report
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-06-01
- Volume
- 8
- Issue
- 3
- Pages
- 179-191
- ISSN
- 2052-0034 (ISSN-L)
- PMC
- PMC7333932
- OpenAlex
- W3037750477
- Cited by
- 119
- References
- 166
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 23 · 2023: 17 · 2022: 23 · 2021: 17 · 2020: 1
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Gastroenterology report (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81871994, 81701834)
- Guangdong Natural Science Foundation (2019B151502063)
- Guangdong Science and Technology Planning Program (20190202018)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- anti-EGFR therapy, metastatic colorectal cancer, drug resistance, cetuximab, panitumumab, EGFR mutation, KRAS, NRAS, BRAF, HER2 amplification, PIK3CA, PTEN, TP53, MET, HER3, insulin receptor substrate 2, FGFR1, MEK1, insulin-like growth factor I, mismatch repair deficiency, epigenetic instability, Ras/Raf/MEK signaling, PI3K/AKT/mTOR pathway, combination therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.